ST. LOUIS, July 10, 2024–(BUSINESS WIRE)–Geneoscopy, Inc., a life sciences firm targeted on growing diagnostic exams for the development of gastrointestinal well being, introduced the publication of a examine in The Journal of Molecular Diagnostics, highlighting the analytical validation of ColoSense™, a noninvasive, multi-target stool RNA (mt-sRNA) screening take a look at for colorectal most cancers (CRC) and superior adenomas (AAs) in average-risk people aged 45 and older.
“ColoSense is the primary FDA-approved CRC screening take a look at to leverage stool-based RNA biomarkers, offering a constant sensitivity profile for all average-risk sufferers from the youngest to the older inhabitants – a problem for methylation-based assays,” stated Dr. Erica Barnell, Chief Science and Medical Officer at Geneoscopy. “These examine outcomes place us to proceed advancing diagnostic applied sciences that can assist meet the rising demand for dependable and accessible most cancers screening options for the 44 million Individuals at common danger for CRC.”
The examine, “Analytical Validation of the Multitarget Stool RNA Check for Colorectal Most cancers Screening,” demonstrated ColoSense’s excessive stability, precision, and reproducibility. Researchers evaluated 12 analytical validation research as a part of the pre-market approval utility to the FDA to find out analytical sensitivity, linearity, precision, and robustness, amongst different parameters. Key findings indicated that the take a look at detects low ranges of particular RNA markers and maintains accuracy throughout a variety of testing circumstances. The examine’s information additional validates ColoSense’s assay robustness, which obtained 93% sensitivity for CRC and 45% sensitivity for AAs in average-risk people.
CRC is the second most typical reason for most cancers loss of life in the USA. Nonetheless, tens of millions of Individuals don’t get screened as a consequence of an absence of entry to or avoidance of invasive choices like colonoscopies. Whereas conventional colonoscopy is the gold commonplace for detecting CRC and AAs, noninvasive exams like ColoSense supply a necessary different for sufferers who’re noncompliant with colonoscopy suggestions. The latest decreasing of the really helpful screening age from 50 to 45 years by the USA Preventive Companies Process Pressure and the American Most cancers Society has expanded the necessity for efficient CRC screening strategies.
About Geneoscopy, Inc.
Geneoscopy Inc. is a life sciences firm targeted on growing diagnostic exams for gastrointestinal well being. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy’s mission is to empower sufferers and suppliers to remodel gastrointestinal well being by way of modern diagnostics. The corporate’s FDA-approved ColoSense™ take a look at makes use of a proprietary RNA-based platform to display screen for colorectal most cancers and superior adenomas for average-risk people over the age of 45. In partnership with main universities and biopharmaceutical firms, Geneoscopy can be growing diagnostic exams for therapy choice and remedy monitoring in different GI illness areas. For extra data, go to www.geneoscopy.com and comply with the corporate on LinkedIn.
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20240710490047/en/
Contacts
Media
Andrea Sampson
Sampson Public Relations Group
asampson@sampsonprgroup.com
Investor Relations
Carrie Mendivil / Ji-Yon Yi
Gilmartin Group
buyers@geneoscopy.com
